ERBB2 and gastric cancer: To model GC patient genotype/phenotype differences (e.g., disease subtype, ERBB2 gene amplification vs. protein overexpression, etc.), prior to selection for trastuzumab therapy, we established a panel of 25 highly heterogeneous GC cell lines, using 8 of 14 cell lines from the CCLE, and 17 other cell lines we identified from published literature and public depositories (Additional file 2: Table S1).